Abstract
No-reflow phenomenon is a consequence of percutaneous coronary intervention (PCI) which arises most of the time in the setting of myocardial infarction, but can be also the consequence of PCI in stable angina patients (rotatablator ablation technique or angioplasty in saphenous vein grafts). In this review, we summarize two ways of treating the noreflow according to the current literature. First through the pharmacological approach where several compounds have been assessed like adenosine, nitruprusside, verapamil, nicorandil, dipyridamole, epinephrine or cyclosporine. Second through the mechanical approach where few strategies have been examined like intra-aortic ballon pumping or postconditioning. Finally, we provide an algorithm for treating a no-reflow even though no studies showed a beneficial effect in terms of clinical endpoints.
Keywords: No-reflow, slow-flow, myocardial infarction, reperfusion
Current Vascular Pharmacology
Title:Myocardial No-Reflow Treatment
Volume: 11 Issue: 2
Author(s): Olivier Muller, Catalina Trana and Eric Eeckhout
Affiliation:
Keywords: No-reflow, slow-flow, myocardial infarction, reperfusion
Abstract: No-reflow phenomenon is a consequence of percutaneous coronary intervention (PCI) which arises most of the time in the setting of myocardial infarction, but can be also the consequence of PCI in stable angina patients (rotatablator ablation technique or angioplasty in saphenous vein grafts). In this review, we summarize two ways of treating the noreflow according to the current literature. First through the pharmacological approach where several compounds have been assessed like adenosine, nitruprusside, verapamil, nicorandil, dipyridamole, epinephrine or cyclosporine. Second through the mechanical approach where few strategies have been examined like intra-aortic ballon pumping or postconditioning. Finally, we provide an algorithm for treating a no-reflow even though no studies showed a beneficial effect in terms of clinical endpoints.
Export Options
About this article
Cite this article as:
Muller Olivier, Trana Catalina and Eeckhout Eric, Myocardial No-Reflow Treatment, Current Vascular Pharmacology 2013; 11(2) . https://dx.doi.org/10.2174/1570161111311020015
DOI https://dx.doi.org/10.2174/1570161111311020015 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Berberine: Is it a Promising Agent for Mental Disorders Treatment?
Current Molecular Pharmacology Clinical Pharmacotherapy for Obesity: Current Drugs and Those in Advanced Development
Current Drug Targets Protective Effects of Mesenchymal Stem Cells Against Central Nervous System Injury in Heat Stroke
Current Stem Cell Research & Therapy Diversity in Hypertension and Cardiovascular Disease Around the Globe
Current Hypertension Reviews Modifying Anti-Inflammatory Effect of Diclofenac with Murraya koenigii
Recent Patents on Inflammation & Allergy Drug Discovery Hypoglycemic Hemiparesis Masquerading As Ischemic Stroke: When Guideline Fails
Current Drug Therapy Review of Synthesis, Biological Assay, and QSAR Studies of HMGR Inhibitors
Current Topics in Medicinal Chemistry Physiological Pacing - Quo Vadis?
Current Cardiology Reviews Stent Thrombosis and Duration of Dual Antiplatelet Therapy
Current Pharmaceutical Design Vascular Effects of Insulin and Their Relation to Endothelial Dysfunction, Insulin Resistance and Hypertension
Current Hypertension Reviews Congenital Heart Disease in Non-Diabetic Large-for-Gestational-Age (LGA) Neonates
Cardiovascular & Hematological Disorders-Drug Targets Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology
Current Drug Targets Traditional Chinese Medicine in Treatment of Metabolic Syndrome
Endocrine, Metabolic & Immune Disorders - Drug Targets Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry Preface
Current Pharmaceutical Design Oxidative Stress and Nitric Oxide in Autism Spectrum Disorder and Other Neuropsychiatric Disorders
CNS & Neurological Disorders - Drug Targets Management of Patients with Poly-Vascular Disease: Priorities for Revascularization Procedures
Current Vascular Pharmacology Nano Cocrystals: Crystal Engineering from a Nanotechnological Perspective
Current Pharmaceutical Design Antidiabetics Interactions with Herbs: A Compressive Review
Current Diabetes Reviews Genetic Signatures in Ischemic Stroke: Focus on Aspirin Resistance
CNS & Neurological Disorders - Drug Targets